News
MBX Biosciences is advancing a unique prodrug pipeline with key GLP-1 assets and a pivotal Phase 2 readout in ...
2d
Investor's Business Daily on MSNNovo Nordisk Is Shedding Muscle In The Weight-Loss Brawl With Eli LillyNovo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.
4d
Zacks Investment Research on MSNNovo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock Has More Upside?Novo Nordisk NVO and Viking Therapeutics VKTX have emerged as notable players in the obesity space. A market leader in the ...
Whichever way the tariff winds blow (and I've no special knowledge of that), Novo Nordisk stock remains arguably the cheapest ...
The prospect of reducing the risk of some very common cancers adds the weight of evidence behind the GLP-1 agonist class, ...
Despite Lars Fruergaard Jørgensen's resignation as Novo Nordisk's CEO, its stock price has risen 10% over the past two weeks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results